Modeling the effects of tetanus vaccination on chronically infected HIV
  patients by Jones, Laura E. & Perelson, Alan S.
ar
X
iv
:p
hy
sic
s/0
10
90
14
v2
  [
ph
ys
ics
.bi
o-
ph
]  
3 D
ec
 20
01
Modeling the effects of tetanus vaccination
on chronically infected HIV patients
L. E. Jones and A. S. Perelson
Theoretical Biology and Biophysics Group
Los Alamos National Laboratory
Los Alamos, NM 87545
Running Head: Modeling effects of vaccination
Corresponding author: Alan S. Perelson, Theoretical Biology and Biophysics,
MS-K710, Los Alamos National Laboratory, Los Alamos, NM 87545, asp@lanl.gov
Requests for reprints: Alan S. Perelson, Theoretical Biology and Biophysics,
MS-K710, Los Alamos National Laboratory, Los Alamos NM 87545, (505)667-6829,
asp@lanl.gov
This work was performed under the auspices of the U.S. Department of Energy and
was supported by NIH grants AI28433 and RR06555.
Objective: To model the effects of vaccination with a common recall antigen on
chronically infected HIV-1 patients.
Background: T-cell activation plays a critical role in the initiation and propagation
of HIV-1 infection and yet transient activation of the immune system is a normal
response to immunization. While it is now considered wise to vaccinate HIV-1 positive
patients, it is crucial to anticipate any lasting effects of vaccination on plasma HIV-1
RNA levels and on infected T cell populations.
Method: We extend a simple dynamical model of HIV infection to include T cell
activation by vaccination. We show that the model can reproduce many but not all of
the features of the post-tetanus immunization rise in viral load observed and reported
on by Stanley et al. [N. Engl. J. Med., 334:1222–1230 (1996)].
Results and conclusions: Amplitudes and approximate timing of post immuniza-
tion peak viral loads were matched in nine of eleven cases; in patients with double post
immunization peaks of nearly equal amplitude the later peaks were matched. Fur-
thermore, our simulations suggest that productively infected cell populations track
post-vaccination increases in plasma viral load, rising and falling in concert on a pe-
riod of about 4 weeks, while chronically infected cells peak later and remain elevated
over baseline levels for up to six weeks post-vaccination.
Keywords: chronic infection, mathematical models, plasma viral load
Introduction
T-cell activation plays a critical role in HIV infection and progression to AIDS [1–4].
In vitro studies have demonstrated the importance of cell activation in establishing
productive HIV infection. For example, reverse transcription within resting cells
may be incomplete and integration of proviral DNA may not occur, resulting in
abortive infection [5–6]. In contrast, activated peripheral blood mononuclear cells are
readily infected in culture [5–7]. The course of HIV infection in vivo appears to be
influenced by cell activation. High levels of activated peripheral T cells are a predictor
of early progression to AIDS [8–9], and chronic immune activation due to frequent and
repeated parasitic infection has been suggested as the probable cause of the increased
rate of HIV progression to AIDS and the greater susceptibility to infection observed
in sub-Saharan Africa as compared to the developed countries [10–12].
Transient activation of the immune system occurs during infections and is a normal
response to immunization. Such activation can affect the course of HIV infection.
Numerous studies have examined the consequences of vaccinating untreated HIV-
infected individuals [2, 13–17]. Stanley et al. [2] found that giving a booster dose
of tetanus toxoid resulted in transient increases in plasma viremia in all 13 HIV-
infected subjects studied. Staprans et al. [13] found that influenza vaccination led to
transient increases of plasma HIV-1 RNA, and that patients with higher CD4 T-cell
counts had larger and more rapid increases in viral load. The large immunization-
related increases in virus reported by Staprans et al. [13] suggest that the observed
viral replication may be correlated with activation of both antigen-specific T-cells and
other non-specific T-cell populations, which once activated, then become targets for
infection [3].
Other studies using influenza vaccination and pneumococcal vaccine have con-
firmed that vaccination can trigger increases in plasma HIV RNA [14–17]. Thus a
number of data sets are available that illustrate a relationship between immune system
activation and changes in HIV viral load. This data presents an interesting challenge
to current mathematical models of HIV infection [18–20]. In an early theoretical pa-
per, McLean and Nowak [21] examined the effects of infection with pathogens other
than HIV as a cofactor in HIV progression. However, no quantitative data was avail-
able at the time for direct comparison of model and theory. A more recent study
[22] presented a model and some comparisons with averaged data for untreated pa-
tients, but concentrated primarily on antigen-driven T-cell proliferation and residual
viral replication for patients on anti-retroviral therapy. Here we focus on the effects
of vaccination on untreated HIV-infected patients. We construct a simple model of
HIV-infection and immune system activation via vaccination, and then compare the
model with data from the study of Stanley et al. [2] in which 13 HIV seropositive,
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asymptomatic individuals were vaccinated with tetanus toxoid.
A simple vaccination model
To understand the effects of vaccination with a common recall antigen (tetanus toxoid)
on chronically infected, untreated HIV patients whose viral loads have reached steady
state, we modify what has become a standard HIV infection model [18-19]. The
model includes uninfected, infected and chronically infected T-cell populations, HIV
and other antigens A. We assume that the vaccine–introduced antigens, A, activate
CD4+ T-cells. For simplicity, the model ignores latently infected cells, which in
untreated individuals are an extremely minor source of virus; Chun and Siliciano [23]
estimate that only 1 in 105 T cells are latently infected. We also do not separately
consider vaccine-specific or HIV specific T-cell populations, since this leads to a model
with more parameters than the data reported by Stanley et al. [2] will support.
The model, like that of McLean and Nowak [21], includes vaccine antigen A, which
we assume is eliminated from the body at a rate proportional to both the antigen
concentration and the CD4+ T cell density. The rate of proportionality γ implicitly
includes a factor that accounts for the fact that only a fraction of T cells are antigen
specific and accounts for complexities of the antigen specific, helper cell dependent
response that leads to antigen elimination.
Since individuals would be expected to vary with regard to the time of their last
tetanus vaccination, one might assume that levels of antibody and T memory cells
specific for tetanus toxoid would also vary. In our model we avoid this level of detail,
but simply assume that the antigen clearance rate constant, γ, and parameters that
determine the rate of T cell activation vary for each patient.
The model we use is given by the following system of differential equations:
dA
dt
= −γAT(1)
dT
dt
= λ+ a(
A
A +K
)T − dT − kV T(2)
dT ∗
dt
= (1− α)kV T − δT ∗(3)
dC
dt
= αkV T − µC(4)
dV
dt
= NδT ∗ +NcµC − cV(5)
where A is the vaccine antigen, T are uninfected CD4+ T cells, T ∗ are productively
infected cells, C are chronically infected cells, and V represents HIV. Vaccine antigen
is cleared in a T cell-dependent manner with rate constant γ. Uninfected T cells, T ,
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are produced at a rate λ, die at a rate d, and are infected by virus with rate constant
k. In the presence of antigen, we assume T cells are activated into proliferation at
a maximum rate a, and that the proliferation rate depends on the antigen concen-
tration with a half-saturation constant K. K is thus the antigen concentration that
drives T cell proliferation to half its maximal value. Productively infected cells, T ∗,
are generated by infection of target T-cells, T , at a rate kV T , and die at rate δ,
as in the standard model [18]. Chronically infected T-cells, C, are produced from
susceptible T-cells at a rate αkV T , where α < 1. Thus, the production of chronically
infected cells occurs at a fraction of the rate productively infected cells are generated.
Chronically infected cells die at a rate µ, which we assume is less than δ, so that
chronically infected cells are longer-lived than productively infected cells. Free virus,
V , is produced by productively infected cells at average rate Nδ, by chronically in-
fected cells at rate Ncµ, and is cleared at rate c per virion. Based on previous work
we assumed λ = 1 × 104ml−1 [24]; d = 0.01d−1 [25]; δ = 0.7d−1 [18]; α = 0.195 [24];
µ = 0.07d−1 [19]; Nc = 4.11 [24], and c = 13d
−1 [22, 26]. Prior to vaccination, each
patient was assumed to be in steady state with a known total baseline T cell count,
T¯T , and viral load, V¯ .
Given these measurements and the steady-state conditions derived from equations
(1) – (5) (see Appendix), initial numbers of infected cells can be derived as well as a
set of parameters describing chronic HIV infection for each patient.
At time t = 0, we assume a dose of antigen, A0, was given in a vaccine, which
perturbed the steady state. We assume the same dose of vaccine was given to all
individuals, and then model the antigen remaining in each individual as a fraction of
the immunizing dose. This is equivalent to setting A0 = 1. We numerically solve the
system of differential equations given by (1) - (5), with the initial conditions A(0) = 1,
and T , T ∗, C, and V set to their steady state values. For each individual studied,
the parameters K, a and γ were allowed to vary so that the amplitude and timing of
the response could be best matched to the observed post-vaccination viremia.
Data and sampling
Stanley et al. [2] studied 16 asymptomatic homosexual men seropositive for HIV-1.
Thirteen subjects were given an 0.5 ml tetanus booster intramuscularly and three were
mock immunized. After vaccination, viral load measurements were taken on days 0
(baseline), 4, 7, 14, 21, 28 and 42. No information on prior vaccination history, i.e.,
date of last tetanus booster, or general quality of health was given. It was noted that
one patient developed cavitary pneumonia about a month following vaccination.
Of the thirteen patients reported on by Stanley et al. [2], we did not include
patients 12 and 13 in our study. Published data for patient 12 had inconsistencies,
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Table 1. Baseline characteristics and post-immunization plasma viremia
Patient T cells, TT T¯ T¯ ∗ C¯ V0 † Vp Vp/V0
cells/mm3 cells/mm3 cells/mm3 cells/mm3 RNA/ml RNA/ml
1. 362 336 7.6 18.5 147,000 437,000 (21/20) ‡ 2.97
2. 271 241 8.7 21.1 3,850 10,500 (14,28/14) 2.73
3. 350 323 7.8 18.8 120,000 900,000 (7/8) 7.50
4. 389 364 7.3 17.7 100,000 700,000 (3,21/18) 7.00
5. 586 569 4.9 12.0 21,000 45,000 (3,21/19) 2.14
6. 336 309 7.9 19.3 215,000 725,000 (7/9) 3.37
7. 336 309 7.9 19.3 75,000 315,000 (7,21/18) 4.20
8. 361 335 7.6 18.5 87,500 241,000 (7,21/19) 2.75
9. 497 476 6.0 14.6 220,000 745,000 (7,21/23) 3.38
10. 615 599 4.6 11.1 10,500 375,000 (7/7) 35.7
11. 363 337 7.6 18.5 80,000 225,000 (7,21/18) 2.81
† V0 = baseline viral load, Vp = peak viremia
‡ First number(s) are observed time(s); second number, modeled time to peak viremia (d).
and patient 13 had a T-cell count, TT , of 8 cells per mm
3, which is too low to
be consistent with our parameter assumptions and the pre-vaccination steady state
assumption of our model (see Appendix). Thus either the patient was not at true
steady state, or the parameter values chosen from the literature are not applicable to
this patient. The baseline characteristics for the remaining eleven patients are given
in Table 1.
Data obtained for a subset of the patients are shown in Figures 1a and 1b. The
data sampling was too sparse to determine the exact peak of viremia or the time the
peak was attained. However, Stanley et al.[2] report the apparent peak and the time
it was measured. Many patients had two post-immunization peaks in viral load. The
larger peak was the earlier of the two observed peaks in patients 3, 5, 10, and the
second of two peaks in patients 1, 4, 7, and 11. Patients 2, 8, and 9 had two peaks of
nearly equal amplitude (Figure 1a).
Of the patients with double post-immunization peaks in viremia, patients 1, 7, 8,
9 and 11 had peaks at days 7 and 21 (Figure 1a), though in some of these cases the
earlier peak can be classified as a minor peak or an inflection point. Of those with
single observed post-immunization peaks, patients 3, 5, and 10 have primary peaks
at day 7, and inflection points, shoulders, or minor peaks at day 28 (Figure 1b).
Results
For each of the eleven patients studied, the model was fit to the data on viral load
changes after vaccination. Using nonlinear regression techniques, the best-fit set of
parameters were then determined for each patient (Table 2).
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Table 2. Best-fit parameter values for modeling post-immunization plasma viremia
Patient No. k N a K γ
ml/d d−1 ml/d
1. 1.3452 × 10−7 356 3.66 187.1 3.8199 × 10−8
2. 8.1743 × 10−6 7 1.8 41.1 4.2732 × 10−7
3. 1.7437 × 10−7 285 1.60 3.36 1.7475 × 10−6
4. 1.7475 × 10−7 253 1.02 31.3 1.0001 × 10−8
5. 3.6064 × 10−7 78 0.78 3.68 6.6248 × 10−6
6. 1.0411 × 10−7 501 2.49 2.20 1.0258 × 10−5
7. 2.9845 × 10−7 174 3.63 169.0 1.5195 × 10−8
8. 2.2705 × 10−7 211 2.00 95.2 6.4431 × 10−8
9. 4.9959 × 10−8 678 1.96 115.2 9.1986 × 10−8
10. 6.3697 × 10−7 41 1.75 0.39 3.08277 × 10−6
11. 2.4603 × 10−7 194 1.91 86.3 1.0660 × 10−7
The amplitude and the approximate timing of the post-immunization maximum
viremia were matched in nine of eleven cases; in patients with double peaks of nearly
equal amplitude (i.e., patients 8, 9), the later peaks were matched. The results are
summarized in Tables 1 and 2.
Early peaks in post-vaccination plasma viral load
Patients with relatively high baseline CD4 T-cell counts (patients 5, 9, 10), as well as
those with high baseline viremia (patients 6, 9) all had early peak viremia, at either
3 days (patient 5) or 7 days (patients 6, 9, 10) post-immunization. This is reasonable
since patients with a high baseline T-cell count or high viral load would be expected to
have a larger population of target cells that could respond post-immunization. Thus,
a vigorous early response by the immune system ensures an early peak in viremia.
The “viremia factor”, or ratio of peak viremia to baseline viremia, given as Vp/V0
in Table 1, was generally rather low for most patients, ranging between 2 and 4 (mean
= 2.92) for nine of twelve patients. Three remaining patients with unusually high
“viremia factor” ratios, patients 3 (Vp/V0 = 7.5), 4 (Vp/V0 = 7.0) and 10 (Vp/V0 =
35.7) also had early peaks, though in patient 4 this was a minor inflection followed
by peak viremia at 21 days, whereas both patients 3 and 10 had single early peaks.
We were able to match well the amplitude and timing of peak viremia for patients
3, 6, and 10 (Figure 2), all of whom had early peaks in viremia and were best-fit with
relatively high antigen clearance rate constants, γ, in our simulations (Table 2).
Double peaks in post-vaccination plasma viral load
Over half of the patients studied had multiple peaks in viremia, though often the first
peak might be classified as ‘minor’. For patients with a minor early peak, usually
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at day 7, followed by a maximum in viral load at day 21, we were able to fit the
amplitude and timing of the maximum peak. Patients 1, 4, 7, and 11 exemplify this
behavior; results for patient 1 are shown in Figure 2. These patients were best-fit
with γ values that were low relative to those given for patients with true early peaks
in viremia (Table 2). Patient 5 had very early viremia [day 4] followed by a second
peak at day 21. We were able to model the second peak, and from this obtained a
relatively high antigen clearance constant.
Some patients experienced early and late peaks in viremia of equal or nearly equal
amplitude. Of the patients with double peaks in viremia, our model generally fit
the later peak at day 21. These patients were assigned much lower clearance rates
then were the patients who experienced single early peaks in viremia. However, in
patients with double peaks (e.g., patients 8 and 9, Figure 2) fits to the earlier peaks,
unobtainable with this model, might require higher values of γ.
T-cell - Antigen Interactions
The rate of antigen induced T-cell activation/proliferation is given in the model by
a( A
A+K
) [equations 2 and 7]. Recall that the antigen concentration has been normal-
ized, so that A0 = 1 and A ≤ 1. Thus, the initial rate of interaction, which is the
highest rate since the antigen has not yet decayed, is given by a( 1
1+K
) For patients
1, 2, 4, 7, 8, 9, and 11, K >> 1 (Table 2). Thus, the denominator in the T cell
activation term is approximately equal to K, and the initial activation/proliferation
rate is ∼ a
K
.
Substituting in K and a values (Table 2) for these patients yields initial a/K
values ranging from 0.017 d−1 to 0.043 d−1 (mean value ± sample standard deviation
0.025 ± 0.0095 d−1) with most values clustered around 0.02 d−1. These patients all
had low values for the T-cell activation/proliferation term, and late peaks (day 21)
in observed and modeled viremia.
Higher initial values of the activation term would increase the interaction between
T-cells and antigen A, resulting in swifter activation of T-cells and an earlier increase
in virus. For patients 3, 5, 6, and 10, A0 and K were the same order of magnitude
or within one order of magnitude in value, and the approximation for the interaction
term shown above does not hold. In this case, the initial interaction term for these
patients ranged from 0.21 d−1 to 4.5 d−1 (mean value 1.6 ± 1.9), which is between
one and two orders of magnitude greater than the interaction terms found for the
prior group of ‘late peaking’ patients. Patients 3, 6, and 10 all had early viremia,
and relatively high values for the antigen clearance term γ. Note that patient 5 also
had an early peak in observed viremia at day 4 that we could not fit with this model.
Patient 5 had a second peak in viral load which we could fit, obtaining both a high
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initial interaction rate and a high antigen clearance rate. In patients 5 and 10, the
large interaction term and antigen clearance rates may reflect relatively high baseline
T-cell levels.
The parameter a in our model represents the maximum rate of antigen–driven
T-cell proliferation. From Table 2, the mean ± sample standard deviation of a =
2.1± 0.91. For a cell population dividing at rate a, 1/a (days) is the average division
time. Using the parameter estimates from Table 2, one can compute the mean of 1/a,
and find that the mean value of average division times is .59± 0.30 (days) or 14± 7.1
(hours).
Productively and Chronically infected cells
Of concern for HIV-infected patients are any potentially long-lasting effects, aside
from protective immunity to the vaccine antigen, associated with immunization. Ac-
cording to our model, the density of productively infected cells, T ∗, tracks changes
in viral load, peaking and falling at the same time. The effects of vaccination on
longer lived chronically infected cells, C, however, are more lingering. According to
our model, the ratio of maximum chronically infected cell level over baseline for all
but one patient ranged from 1.6 to 3.6, with a mean of 3.4±0.22, and the one outlier
value of a 13–fold increase in chronically infected cells [patient 10]. At 28 days post
immunization, our simulations show these long-lived cells still elevated with respect
to their initial (steady state) values, yielding increases of 1.4 to 3.0 over baseline,
with a mean of 1.9 ± 0.51, disregarding the outlier value which is still high at 4.3
above baseline. At 42 days post immunization, chronically infected cells are still a
factor of 1.3± 0.46 on average above baseline, again disregarding the outlier value of
1.9 above baseline. Indeed, focusing only on late-peaking patients, for whom infected
and chronically infected cells are later to reach maximum, yields ratios of 2.0± 0.22
at maximum, 2.0 ± 0.28 at 28 days, and 1.4 ± 0.22 at 42 days. By contrast, at 42
days post immunization, productively infected cells for both patient populations have
achieved or fallen below their baseline values. Modeled infected cell densities from
patient 10 are shown plotted against plasma viral load (Figure 3); note that chroni-
cally infected cells remain elevated long after infected cell populations have fallen to
baseline values even in this early peaking patient. Thus while vaccination gives rise to
short-term changes in viral load and productively infected cells, it may also produce
longer lasting increases in the populations of chronically infected cells.
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Discussion
With a simple modification of a standard HIV-infection model that takes into account
antigen-driven proliferation of T cells, we are able to reproduce the general features
of the post-vaccination rise in viral load reported on by Stanley et al. [2]. This
implies that simply increasing the number of cells susceptible to infection by antigen
activation, i.e., vaccination, can account for the modest rises in viral load observed by
Stanley et al. [2] after tetanus booster vaccination. Interestingly, more than half of
the patients in this study had double peaks in plasma HIV-1 RNA post-vaccination.
While assay variability might account for some of these peaks, in other cases the peaks
were sufficiently large that this seems unlikely. For patients with double peaks we
were only able to fit the later of the two peaks, which was often the larger peak. These
patients were assigned lower pathogen clearance rate constants, γ, than patients with
early single peaks in viremia, which we also successfully modeled.
The fact that we could not approximate the earlier peaks in those patients with
double peaks in viremia suggests that our model may lack some features present in
the actual biology. For example, individuals vaccinated recently may have a larger
and more robust memory cell response than individuals vaccinated a long time in the
past. The two peaks may represent an early memory response followed by a naive cell
response. In individuals with little remaining memory, one may speculate that only
the later naive response would be observed. However, since the two peaks frequently
occur 14 days apart, this explanation would require a substantial difference in the
time to activate naive and memory cell responses. Another possible explanation for
double peaks is that the first peak is due to stimulation and infection of tetanus
specific T cells, whereas the second peak is caused by the rise in viremia stimulating
HIV specific T cells, or increasing the level of immune system activation, which in
turn leads to an increase in target cell availability. We do not favor this explanation
because our model, which follows the activation of T cells by antigen, had difficulty
mimicking the fast rise in viremia needed to explain an early peak. One can speculate
then that the early peak is not due to the infection of vaccine-induced target cells, but
rather to an effect such as the cytokine-induced enhancement of HIV transcription
and release from infected cells as has been seen in vitro with the use of tumor necrosis
factor-α [5].
Despite the fact that the model failed to reproduce double peaks in viral load,
the model could account for the timing and amplitude of the major peak in post-
vaccination plasma viremia. Because HIV-1, as observed in plasma, is produced
by infected cells, the model suggests that levels of both productively infected and
chronically infected cells also increase due to vaccination. Levels of latently infected
cells presumably also increase, but in untreated individuals this population makes
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a minor contribution to plasma viral load. According to the model the increase
in productively infected cells mirrored the observed changes in plasma viral load,
and due to the short lifespan of these cells led to little long-term perturbation of
this population. However, chronically infected cells have longer lifetimes and hence
vaccination led to a larger period of increase in this population. Nevertheless, in all
but one patient the increase was not large, with the maximum increase being 3.6–fold,
and in the most extreme case studied here, the increase was 13–fold. However, by
day 42 the chronically infected cell elevations were less than 2-fold in all patients.
This, coupled with the fact that chronically infected cells generally produce only 1-
7% of plasma virus [19], implies that the long-term impact of this change on disease
progression should be small.
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Appendix
The steady state productively infected and chronically infected cell concentrations,
T¯ ∗, and C¯, the infection rate constant, k, and burst size, N , may be calculated
from the following steady state equations, derived by setting the left-hand sides of
equations (2)-(5) to zero.
k =
λ− dT¯
V¯ T¯
(6)
T¯ ∗ =
1
δ
(1− α)(λ− dT¯ )(7)
C¯ =
α
µ
(λ− dT¯ )(8)
N =
cV¯ −NcµC¯
δT¯ ∗
(9)
In addition, we impose the following conservation rule:
T¯T = T¯ + T¯ ∗ + C¯(10)
where T¯T is the observed (total) T-cell count, comprising uninfected cells T¯ , produc-
tively infected cells T¯ ∗, and chronically infected cells C¯. From the above condition
and equations (7) and (8), we derive the following relation for T¯ :
T¯ =
δµT¯T − λ[(1− α)µ+ αδ]
δµ− d[(1− α)µ+ αδ]
(11)
Parameters other than k and N were set as indicated in the text. Note that with
these parameter choices, and the measured baseline T cell and viral load levels in
the patients studied by Stanley et al. [2] this model generally yields larger steady
state levels of chronically infected cells than of productively infected cells in these
untreated patients (Table 2).
Note that according to equation (11), the T cell count at steady state has to be
larger than a minimal value for the numerator of equation (11) to be positive. For
patient 13, with a T cell count of 8 cells per µl, this condition is violated due to our
choice of fixed parameters that were originally chosen from published data related to
less advanced patients.
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Figure 1: Data from [2] showing post-vaccination rises in plasma HIV-1 RNA. (A.) Patients
experiencing two distinct peaks in viremia at roughly days 7 and 21. Patients 8 and 9 have equal
or nearly equal peaks at days 7 and 21, while patients 1, 7, and 11 experience what was recorded
as a minor peak at day 7 followed by a true peak at day 21. (B.) Patients experiencing one early
primary peak in viremia at day 7. Note that the curves for most of these patients show a post-peak
’shoulder’ at days 21-28.
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Figure 2: Comparison of model (solid line) with data (red triangles). Note that in some cases data
sampling is such that the data curve is slightly asymmetric, and the true peak may not have been
sampled. Modeled Patient 6 experienced a second very late peak (42 days) associated with known
cavitary pneumonia, so the data is truncated at 28 days.
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Figure 3: Modeled post-vaccination infected cell density and HIV-1 plasma viral load for patient 10.
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